• Overview
    Overview
  • Revenue
    Revenue
  • Segments
    • Revenue by Product
    • Revenue by Region
    Segments
  • Financials
    • Income Statement
    • Balance Sheet
    • Cashflow Statements
    • Profitability
    • Ratios
    Financials
  • People
    • CEO Salary
    • Employees
    • Revenue per Employee
    • Net Income per Employee
    People
  • OwnershipOwnership
    Ownership
  • Competitors
    Competitors
  • Stocks
    • Market Cap
    • PE Ratio
    • Stock Split
    • Dividend
    Stocks
  • News
    • Company News
    • Press Releases
    News
  • Earnings Calls
    Earnings Calls
  • Documents
    • Annual Reports
    • Quarterly Reports
    • SEC Filings
    Documents
Submit Feedback
Submit Feedback (Sign in required)
Bullfincher logo
Recent searches
    Trending searches
    • Company logo Caterpillar Overview
    • Company logo Apple Revenue
    • Company logo NVIDIA Corporation Employees
    • Company logo Microsoft Corporati... Revenue by segment
    • Company logo Amazon.com Financials
    • Company logo Tesla Overview
    • Home
    • Companies
    • Calendars
    • Ranking
    • Blog
    • Login

    Submit feedback to Bullfincher

    LLY logo Eli Lilly and Company +
    LLY logo
    Eli Lilly and Company
    +
    • Overview
    • Revenue
    • Segments
      • Revenue by Product
      • Revenue by Region
    • Financials
      • Income Statement
      • Balance Sheet
      • Cashflow Statement
      • Profitability
      • Ratios
    • People
      • CEO Salary
      • Employees
      • Revenue per Employee
      • Net Income per Employee
    • Ownership
    • Competitors
    • Stocks
      • Market Cap
      • PE Ratio
      • Stock Split
      • Dividend
    • News
      • Company News
      • Press Releases
    • Earnings Calls
    • Documents
      • Annual Report 10K
      • Quarterly Report 10Q
      • SEC Filings
    LLY logo Eli Lilly... LLY + Follow
    • Revenue
    • Employees
    • Market Capitalization

    Eli Lilly and Company's Revenue (2016 - 2025)

    • Eli Lilly and Company's annual revenue was $65.18 B in fiscal year 2025. The annual revenue increased $20.14 B from $45.04 B (in 2024) to $65.18 B (in 2025), representing a 44.70% year-over-year growth.

    • Eli Lilly and Company's quarterly revenue was $19.80 B in the quarter ending Mar 2026. The quarterly revenue increased $7.07 B from $12.73 B (in Q1: Dec 2025) to $19.80 B (in Q1: Dec 2026), representing a 55.55% year-over-year growth.

    • Over the past 10 years (2016 - 2025):
    • The highest annual revenue for Eli Lilly and Company was $65.18 B in fiscal year 2025.
    • The lowest annual revenue was $19.97 B in fiscal year 2017.
    • The average revenue was $31.08 B.

    • Learn more about Eli Lilly and Company's Revenue by Segment and Revenue by Region.

      Check out competitors to Eli Lilly and Company in a side-by-side comparison.

      Explore additional financial metrics for Eli Lilly and Company.


      Definition of Revenue :
    • Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
    Continue reading...

    Eli Lilly and Company's Revenue Trend

    2015 19958700000.00
    2016 21222100000.00
    2017 19973800000.00
    2018 21493300000.00
    2019 22319500000.00
    2020 24539800000.00
    2021 28318400000.00
    2022 28541400000.00
    2023 34124100000.00
    2024 45042700000.00
    2025 65179000000.00
    Mar 2016 4865100000.00
    Jun 2016 5404800000.00
    Sep 2016 5191700000.00
    Dec 2016 5760500000.00
    Mar 2017 5228300000.00
    Jun 2017 5824300000.00
    Sep 2017 5658000000.00
    Dec 2017 6160700000.00
    Mar 2018 4963800000.00
    Jun 2018 5585000000.00
    Sep 2018 5306900000.00
    Dec 2018 6438600000.00
    Mar 2019 5092200000.00
    Jun 2019 5636700000.00
    Sep 2019 5476600000.00
    Dec 2019 6114000000.00
    Mar 2020 5859800000.00
    Jun 2020 5499400000.00
    Sep 2020 5740600000.00
    Dec 2020 7440000000.00
    Mar 2021 6805600000.00
    Jun 2021 6740100000.00
    Sep 2021 6772800000.00
    Dec 2021 7999900000.00
    Mar 2022 7810000000.00
    Jun 2022 6488000000.00
    Sep 2022 6941600000.00
    Dec 2022 7301800000.00
    Mar 2023 6960000000.00
    Jun 2023 8312100000.00
    Sep 2023 9498600000.00
    Dec 2023 9353400000.00
    Mar 2024 8768000000.00
    Jun 2024 11302800000.00
    Sep 2024 11439100000.00
    Dec 2024 13532800000.00
    Mar 2025 12728500000.00
    Jun 2025 15557700000.00
    Sep 2025 17600800000.00
    Dec 2025 19292000000.00
    Mar 2026 19799000000.00

    2025

    Eli Lilly and Company's annual revenue was $65.18 B in fiscal year 2025.

    Eli Lilly and Company's quarterly revenue was $12.73 B(Q1: Mar 2025), $15.56 B(Q2: Jun 2025), $17.60 B(Q3: Sep 2025), $19.29 B(Q4: Dec 2025) in fiscal year 2025.

    2024

    Eli Lilly and Company's annual revenue was $45.04 B in fiscal year 2024.

    Eli Lilly and Company's quarterly revenue was $8.77 B(Q1: Mar 2024), $11.30 B(Q2: Jun 2024), $11.44 B(Q3: Sep 2024), $13.53 B(Q4: Dec 2024) in fiscal year 2024.

    2023

    Eli Lilly and Company's annual revenue was $34.12 B in fiscal year 2023.

    Eli Lilly and Company's quarterly revenue was $6.96 B(Q1: Mar 2023), $8.31 B(Q2: Jun 2023), $9.50 B(Q3: Sep 2023), $9.35 B(Q4: Dec 2023) in fiscal year 2023.

    2022

    Eli Lilly and Company's annual revenue was $28.54 B in fiscal year 2022.

    Eli Lilly and Company's quarterly revenue was $7.81 B(Q1: Mar 2022), $6.49 B(Q2: Jun 2022), $6.94 B(Q3: Sep 2022), $7.30 B(Q4: Dec 2022) in fiscal year 2022.

    2021

    Eli Lilly and Company's annual revenue was $28.32 B in fiscal year 2021.

    Eli Lilly and Company's quarterly revenue was $6.81 B(Q1: Mar 2021), $6.74 B(Q2: Jun 2021), $6.77 B(Q3: Sep 2021), $8.00 B(Q4: Dec 2021) in fiscal year 2021.

    2020

    Eli Lilly and Company's annual revenue was $24.54 B in fiscal year 2020.

    Eli Lilly and Company's quarterly revenue was $5.86 B(Q1: Mar 2020), $5.50 B(Q2: Jun 2020), $5.74 B(Q3: Sep 2020), $7.44 B(Q4: Dec 2020) in fiscal year 2020.

    2019

    Eli Lilly and Company's annual revenue was $22.32 B in fiscal year 2019.

    Eli Lilly and Company's quarterly revenue was $5.09 B(Q1: Mar 2019), $5.64 B(Q2: Jun 2019), $5.48 B(Q3: Sep 2019), $6.11 B(Q4: Dec 2019) in fiscal year 2019.

    2018

    Eli Lilly and Company's annual revenue was $21.49 B in fiscal year 2018.

    Eli Lilly and Company's quarterly revenue was $4.96 B(Q1: Mar 2018), $5.59 B(Q2: Jun 2018), $5.31 B(Q3: Sep 2018), $6.44 B(Q4: Dec 2018) in fiscal year 2018.

    2017

    Eli Lilly and Company's annual revenue was $19.97 B in fiscal year 2017.

    Eli Lilly and Company's quarterly revenue was $5.23 B(Q1: Mar 2017), $5.82 B(Q2: Jun 2017), $5.66 B(Q3: Sep 2017), $6.16 B(Q4: Dec 2017) in fiscal year 2017.

    2016

    Eli Lilly and Company's annual revenue was $21.22 B in fiscal year 2016.

    Eli Lilly and Company's quarterly revenue was $4.87 B(Q1: Mar 2016), $5.40 B(Q2: Jun 2016), $5.19 B(Q3: Sep 2016), $5.76 B(Q4: Dec 2016) in fiscal year 2016.

    Continue reading...

    Eli Lilly and Company's Revenue (Year-over-Year Change)

    2015 0
    2016 +6.33
    2017 -5.88
    2018 +7.61
    2019 +3.84
    2020 +9.95
    2021 +15.40
    2022 +0.79
    2023 +19.56
    2024 +32.00
    2025 +44.70
    Q1: Mar 16 4.75
    Q2: Jun 16 8.56
    Q3: Sep 16 4.68
    Q4: Dec 16 7.16
    Q1: Mar 17 7.47
    Q2: Jun 17 7.76
    Q3: Sep 17 8.98
    Q4: Dec 17 6.95
    Q1: Mar 18 -5.06
    Q2: Jun 18 -4.11
    Q3: Sep 18 -6.21
    Q4: Dec 18 4.51
    Q1: Mar 19 2.59
    Q2: Jun 19 0.93
    Q3: Sep 19 3.20
    Q4: Dec 19 -5.04
    Q1: Mar 20 15.07
    Q2: Jun 20 -2.44
    Q3: Sep 20 4.82
    Q4: Dec 20 21.69
    Q1: Mar 21 16.14
    Q2: Jun 21 22.56
    Q3: Sep 21 17.98
    Q4: Dec 21 7.53
    Q1: Mar 22 14.76
    Q2: Jun 22 -3.74
    Q3: Sep 22 2.49
    Q4: Dec 22 -8.73
    Q1: Mar 23 -10.88
    Q2: Jun 23 28.11
    Q3: Sep 23 36.84
    Q4: Dec 23 28.10
    Q1: Mar 24 25.98
    Q2: Jun 24 35.98
    Q3: Sep 24 20.43
    Q4: Dec 24 44.68
    Q1: Mar 25 45.17
    Q2: Jun 25 37.64
    Q3: Sep 25 53.87
    Q4: Dec 25 42.56
    Q1: Mar 26 55.55

    2025

    Eli Lilly and Company’s annual revenue increased +44.70% during fiscal year 2025 compared to 2024. It represents a growth of $20.14 B from $45.04 B (in 2024) to $65.18 B (in 2025).

    2024

    Eli Lilly and Company’s annual revenue increased +32.00% during fiscal year 2024 compared to 2023. It represents a growth of $10.92 B from $34.12 B (in 2023) to $45.04 B (in 2024).

    2023

    Eli Lilly and Company’s annual revenue increased +19.56% during fiscal year 2023 compared to 2022. It represents a growth of $5.58 B from $28.54 B (in 2022) to $34.12 B (in 2023).

    2022

    Eli Lilly and Company’s annual revenue increased +0.79% during fiscal year 2022 compared to 2021. It represents a growth of $223.00 M from $28.32 B (in 2021) to $28.54 B (in 2022).

    2021

    Eli Lilly and Company’s annual revenue increased +15.40% during fiscal year 2021 compared to 2020. It represents a growth of $3.78 B from $24.54 B (in 2020) to $28.32 B (in 2021).

    2020

    Eli Lilly and Company’s annual revenue increased +9.95% during fiscal year 2020 compared to 2019. It represents a growth of $2.22 B from $22.32 B (in 2019) to $24.54 B (in 2020).

    2019

    Eli Lilly and Company’s annual revenue increased +3.84% during fiscal year 2019 compared to 2018. It represents a growth of $826.20 M from $21.49 B (in 2018) to $22.32 B (in 2019).

    2018

    Eli Lilly and Company’s annual revenue increased +7.61% during fiscal year 2018 compared to 2017. It represents a growth of $1.52 B from $19.97 B (in 2017) to $21.49 B (in 2018).

    2017

    Eli Lilly and Company’s annual revenue decreased -5.88% during fiscal year 2017 compared to 2016. It represents a decline of $1.25 B from $21.22 B (in 2016) to $19.97 B (in 2017).

    2016

    Eli Lilly and Company’s annual revenue increased +6.33% during fiscal year 2016 compared to 2015. It represents a growth of $1.26 B from $19.96 B (in 2015) to $21.22 B (in 2016).

    Continue reading...

    Eli Lilly and Company Revenue History

    Sign in to download table

    Period Revenue Year-over-Year Change

    Get instant access to data, Sign up for free

    FY 2025
    $65.18 B $20.14 B 44.7%
    Q4: Dec 25 $19.29 B $5.76 B 42.56%
    Q3: Sep 25 $17.60 B $6.16 B 53.87%
    Q2: Jun 25 $15.56 B $4.25 B 37.64%
    Q1: Mar 25 $12.73 B $3.96 B 45.17%

    Get instant access to data, Sign up for free

    FY 2024
    $45.04 B $10.92 B 32%
    Q4: Dec 24 $13.53 B $4.18 B 44.68%
    Q3: Sep 24 $11.44 B $1.94 B 20.43%
    Q2: Jun 24 $11.30 B $2.99 B 35.98%
    Q1: Mar 24 $8.77 B $1.81 B 25.98%

    Get instant access to data, Sign up for free

    FY 2023
    $34.12 B $5.58 B 19.56%
    Q4: Dec 23 $9.35 B $2.05 B 28.1%
    Q3: Sep 23 $9.50 B $2.56 B 36.84%
    Q2: Jun 23 $8.31 B $1.82 B 28.11%
    Q1: Mar 23 $6.96 B -$850.00 M 10.88%

    Get instant access to data, Sign up for free

    FY 2022
    $28.54 B $223.00 M 0.79%
    Q4: Dec 22 $7.30 B -$698.10 M 8.73%
    Q3: Sep 22 $6.94 B $168.80 M 2.49%
    Q2: Jun 22 $6.49 B -$252.10 M 3.74%
    Q1: Mar 22 $7.81 B $1.00 B 14.76%

    Get instant access to data, Sign up for free

    FY 2021
    $28.32 B $3.78 B 15.4%
    Q4: Dec 21 $8.00 B $559.90 M 7.53%
    Q3: Sep 21 $6.77 B $1.03 B 17.98%
    Q2: Jun 21 $6.74 B $1.24 B 22.56%
    Q1: Mar 21 $6.81 B $945.80 M 16.14%

    Get instant access to data, Sign up for free

    FY 2020
    $24.54 B $2.22 B 9.95%
    Q4: Dec 20 $7.44 B $1.33 B 21.69%
    Q3: Sep 20 $5.74 B $264.00 M 4.82%
    Q2: Jun 20 $5.50 B -$137.30 M 2.44%
    Q1: Mar 20 $5.86 B $767.60 M 15.07%

    Get instant access to data, Sign up for free

    FY 2019
    $22.32 B $826.20 M 3.84%
    Q4: Dec 19 $6.11 B -$324.60 M 5.04%
    Q3: Sep 19 $5.48 B $169.70 M 3.2%
    Q2: Jun 19 $5.64 B $51.70 M 0.93%
    Q1: Mar 19 $5.09 B $128.40 M 2.59%

    Get instant access to data, Sign up for free

    FY 2018
    $21.49 B $1.52 B 7.61%
    Q4: Dec 18 $6.44 B $277.90 M 4.51%
    Q3: Sep 18 $5.31 B -$351.10 M 6.21%
    Q2: Jun 18 $5.59 B -$239.30 M 4.11%
    Q1: Mar 18 $4.96 B -$264.50 M 5.06%

    Get instant access to data, Sign up for free

    FY 2017
    $19.97 B -$1.25 B 5.88%
    Q4: Dec 17 $6.16 B $400.20 M 6.95%
    Q3: Sep 17 $5.66 B $466.30 M 8.98%
    Q2: Jun 17 $5.82 B $419.50 M 7.76%
    Q1: Mar 17 $5.23 B $363.20 M 7.47%

    Get instant access to data, Sign up for free

    FY 2016
    $21.22 B $1.26 B 6.33%
    Q4: Dec 16 $5.76 B $384.90 M 7.16%
    Q3: Sep 16 $5.19 B $232.00 M 4.68%
    Q2: Jun 16 $5.40 B $426.10 M 8.56%
    Q1: Mar 16 $4.87 B $220.40 M 4.75%

    Frequently Asked Questions

    What is the annual revenue of Eli Lilly and Company?

    In fiscal year 2025, Eli Lilly and Company's revenue was $65.18 Billion.

    How much did Eli Lilly and Company's revenue change in the last year?

    Eli Lilly and Company's revenue increased by +44.70% (+$20.14 Billion) in 2025 compared to 2024.

    What is Eli Lilly and Company's most recent quarterly revenue?

    In the first quarter (Q1) of 2026, Eli Lilly and Company reported a revenue of $19.80 Billion.

    What is Eli Lilly and Company's revenue per share (TTM)?

    Eli Lilly and Company's revenue per share over the trailing twelve months is $80.77.

    What is Eli Lilly and Company's revenue per employee?

    In the fiscal year 2025, Eli Lilly and Company's revenue per employee was $1.30 Million.

    What is the annual net income of Eli Lilly and Company?

    In fiscal year 2025, Eli Lilly and Company's net income was $20.64 Billion.

    What is Eli Lilly and Company's biggest product segment, and what is its revenue?

    Product is Eli Lilly and Company's biggest product segment, generating $60.96 Billion in revenue for fiscal year 2025.

    What is Eli Lilly and Company's net income per employee?

    In the fiscal year 2025, Eli Lilly and Company's net income per employee was $412.77 K.

    Related

    • A logo Agilent Technologies Revenue
    • SYK logo Stryker Corporation Revenue
    • JNJ logo Johnson & Johnson Revenue
    • ABBV logo AbbVie Revenue
    • MRK logo Merck & Co. Revenue
    • TMO logo Thermo Fisher Scientific Revenue
    • ABT logo Abbott Laboratories Revenue
    • DHR logo Danaher Corporation Revenue
    • AMGN logo Amgen Revenue

    People Also Search For

    • CAT logo Caterpillar
    • AAPL logo Apple
    • NVDA logo NVIDIA Corporation
    • MSFT logo Microsoft Corporation
    • AMZN logo Amazon.com
    • TSLA logo Tesla
    • GOOGL logo Alphabet (Google)
    • NKE logo NIKE
    • WMT logo Walmart
    • META logo Meta Platforms (Facebook)
    • PEP logo PepsiCo
    • TGT logo Target Corporation
    footer logo

    Bullfincher is a “visual-first” business intelligence and research platform. We believe that behind every great company, there is a great story. At Bullfincher, we make story-telling a little easier using dynamic visuals, charts, and graphs.

    explore
    • About Us
    • Blog
    • FAQ
    • Glossary
    Discover
    • Privacy Policy
    • Contact us
    • Submit Feedback
    • Advertise with Us
    Subscribe to our Newsletter !

    Don’t worry, we won’t spam you.

    Disclaimers - All data and information is provided “as is” for informational purposes only and is not intended for trading purposes or financial, investment, tax, legal, accounting, or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. Bullfincher is not an investment adviser, financial adviser, or a securities broker.None of the data and information constitutes investment advice nor an offering, recommendation, or solicitation by Bullfincher to buy, sell, or hold any security or financial product, and Bullfincher makes no representation (and has no opinion) regarding the advisability or suitability of any investment.

    None of the data and information constitutes investment advice (whether general or customized). The financial products or operations referred to in such data and information may not be suitable for your investment profile and investment objectives or expectations. It is your responsibility to consider whether any financial product or operation is suitable foryou based on your interests, investment objectives, investment horizon, and risk appetite. Bullfincher shall not be liable for any damages arising from any operations or investments in financial products referred to within. Bullfincher does not recommend using the data and information provided as the only basis for making any investment decision.

    Bullfincher 2026, All rights reserved

    Submit feedback to Bullfincher

    Submit your feedback


    Note: Please upload only jpg and png file and size 5 MB allowed.